Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: Case report and literature review

European Journal of Clinical Pharmacology

Volumn 66, Issue 6, 2010, Pages 547-554

  Crépin, Sabrina ^a   Laroche, Marie Laure ^a   Sarry, Bernard ^a   Merle, Louis ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Alkylbiphosphonate; Aminobiphosphonate; Biphosphonate; Clodronate; Etidronate; Osteonecrosis of the jaw

Indexed keywords

ALENDRONIC ACID; AMINOGLUTETHIMIDE; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CLODRONIC ACID; ETIDRONIC ACID; FLUOROURACIL; IBANDRONIC ACID; LEUPRORELIN; MITOXANTRONE; NAVELBINE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; STEROID; TILUDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; BONE METASTASIS; BONE REMODELING; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURGERY; CASE REPORT; CLINICAL TRIAL; DRUG EXPOSURE; DRUG POTENCY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCALCEMIA; INCIDENCE; IRRADIATION; JAW OSTEONECROSIS; KIDNEY FAILURE; MEDICAL LITERATURE; MULTIPLE MYELOMA; OSTEITIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; REVIEW; TOOTH PROSTHESIS; TREATMENT INDICATION; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; MANDIBLE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; ORAL SURGERY; PATHOLOGY; TOOTH EXTRACTION;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; CLODRONIC ACID; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MANDIBLE; MIDDLE AGED; ORAL SURGICAL PROCEDURES; OSTEONECROSIS; TOOTH EXTRACTION;

EID: 77954890379     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0822-5     Document Type: Review

References (45)

1. Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222s-6230s
2. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961-2978
3. No authors listed (2005) Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws. LDA J 64:21-24
4. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonateassociated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491
5. Colella G, Campisi G, Fusco V (2009) American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonaterelated osteonecrosis of the jaws - 2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 67:2698-2699
6. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115-1117
7. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-534
8. Wimalawansa SJ (2008) Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf 7:491-512
9. Wang J, Goodger NM, Pogrel MA (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104-1107
10. Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D, Krimmel M (2009) Bisphosphonateinduced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 112:605-609
11. King AE, Umland EM (2008) Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 28:667-677
12. Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415-423
13. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-245 (Pubitemid 12149145)
14. Lannoy D, Decaudin B, Barrier F, Bemba M, Wierre L, Pignon JM, Horrent S, Resibois JP, Wetterwald M, Odou P (2006) Avascular osteonecrosis of the jaws induced by diphosphonates. Therapie 61:363-365
15. Montazeri AH, Erskine JG, McQuaker IG (2007) Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 79:69-71
16. Phal PM, Myall RW, Assael LA, Weissman JL (2007) Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 28:1139-1145
17. Senel FC, Saracoglu Tekin U, Durmus A, Bagis B (2007) Severe osteomyelitis of the mandible associated with the use of nonnitrogen-containing bisphosphonate (disodium clodronate): report of a case. J Oral Maxillofac Surg 65:562-565
18. Starck WJ, Epker BN (1995) Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants 10:74-78
19. Trenque T, Buire A-C, Herlem E, Germain M (2008) Osteonecrosis of the jaw with biphosphonates: french pharmacovigilance data (Abstr 138). Drug Saf 31:885-960
20. Favia G, Pilolli GP, Maiorano E (2009) Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. J Rheumatol 36:2780-2787
21. Favia G, Pilolli GP, Maiorano E (2009) Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45:406-413
22. Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL (2008) Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9:1166-1172
23. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826-836
24. Department of Health and Human services Food and Drug Administration, Center for Drug Evaluation and Research (2005) Osteonecrosis of the jaw. Available at: http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4095T2. pdf. Accessed 14 Aug 2009
25. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S (2007) Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18:1363-1370
26. Etminan M, Aminzadeh K, Matthew IR, Brophy JM (2008) Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 35:691-695
27. Jeffcoat MK (2006) Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 21:349-353
28. Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE (2008) Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35:1391-1397
29. Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567-1575
30. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580-8587
31. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients ofbisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356-5362
32. Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL (2009) Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat 116:433-439
33. Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761
34. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29:1548-1558
35. Watts NB, Marciani RD (2008) Osteonecrosis of the jaw. South Med J 101:160-165
36. Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99-102, discussion 199-1102
37. Palaska PK, Cartsos V, Zavras AI (2009) Bisphosphonates and time to osteonecrosis development. Oncologist 14:1154-1166
38. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91:968-971
39. Marx RE, Cillo JE Jr, Ulloa JJ (2007) Oral bisphosphonateinduced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397-2410
40. Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Vaananen K, Pylkkanen L, Pecherstorfer M, Aapro MS (2007) Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol 64:198-207
41. Van den Wyngaert T, Huizing MT, Vermorken JB (2006) Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 17:1197-1204
42. Reid IR, Bolland MJ, Grey AB (2007) Is bisphosphonateassociated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41:318-320
43. Gutta R, Louis PJ (2007) Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104:186-193
44. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA (2006) Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81:1047-1053
45. Durie BG (2007) Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc 82:516-517, author reply 517-518